MA1-13003

antibody from Invitrogen Antibodies

Targeting: ZPR1 ZNF259

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-13003

Provider

Invitrogen Antibodies

Product name

ZPR1 Monoclonal Antibody (LG1)

Antibody type

Monoclonal

Antigen

Other

Description

MA1-13003 detects ZPR1 in human and mouse samples. MA1-13003 has been successfully been used in Immunofluorescence and Western Blot applications, where a band of ~50 kDa is detected. The immunogen used to produce MA1-13003 was mouse ZPR1 protein.

Reactivity

Human, Mouse

Host

Mouse

Isotype

IgG

Antibody clone number

LG1

Vial size

100 µg

Concentration

1 mg/mL

Storage

-20°C, Avoid Freeze/Thaw Cycles

References

Submitted references

A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN.

Rademacher S, Detering NT, Schüning T, Lindner R, Santonicola P, Wefel IM, Dehus J, Walter LM, Brinkmann H, Niewienda A, Janek K, Varela MA, Bowerman M, Di Schiavi E, Claus P
Cells 2020 Nov 3;9(11)

---

A ZPR1 mutation is associated with a novel syndrome of growth restriction, distinct craniofacial features, alopecia, and hypoplastic kidneys.

Ito YA, Smith AC, Kernohan KD, Pena IA, Ahmed A, McDonell LM, Beaulieu C, Bulman DE, Smidt A, Sawyer SL, Care4Rare Canada Consortium, Dyment DA, Boycott KM, Clericuzio CL
Clinical genetics 2018 Oct;94(3-4):303-312

---

Deficiency of the zinc finger protein ZPR1 causes neurodegeneration.

Doran B, Gherbesi N, Hendricks G, Flavell RA, Davis RJ, Gangwani L
Proceedings of the National Academy of Sciences of the United States of America 2006 May 9;103(19):7471-5

---

ZPR1 is essential for survival and is required for localization of the survival motor neurons (SMN) protein to Cajal bodies.

Gangwani L, Flavell RA, Davis RJ
Molecular and cellular biology 2005 Apr;25(7):2744-56

---

Coupled in vitro import of U snRNPs and SMN, the spinal muscular atrophy protein.

Narayanan U, Achsel T, Lührmann R, Matera AG
Molecular cell 2004 Oct 22;16(2):223-34

---

Spinal muscular atrophy disrupts the interaction of ZPR1 with the SMN protein.

Gangwani L, Mikrut M, Theroux S, Sharma M, Davis RJ
Nature cell biology 2001 Apr;3(4):376-83

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of ZPR1 in MCF-7 Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a ZPR1 monoclonal antibody (Product # MA1-13003) at a dilution of 1:20 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody (Product # 35503). ZPR1 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of ZPR1 in NIH-3T3 Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a ZPR1 monoclonal antibody (Product # MA1-13003) at a dilution of 1:20 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody (Product # 35503). ZPR1 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of ZPR1 in NIH-3T3 Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a ZPR1 monoclonal antibody (Product # MA1-13003) at a dilution of 1:20 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody (Product # 35503). ZPR1 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 Characterization of hSMN S290 phospho-mutant and phospho-mimetic. ( A ) Multiple sequence alignment of the C-termini of SMN from different species showing conservation of serine 290 residue. ( B , C ) Expression of hSMN-FL, hSMN S290D and hSMN S290A in NSC34 cells by Western blot 48 h or 72 h post-transfection (mean +- SEM, n = 6, one-way ANOVA with Sidak post-test, **** p < 0.0001). ( D , E ) Radioactive pulse-chase experiment determined stability of hSMN-FL, hSMN S290D and hSMN S290A. Representative autoradiographs at the same exposure times and decay curves of immunoprecipitated hSMN-FL, hSMN S290D, and hSMN S290A (mean +- SEM, n = 3, non-linear regression, one phase decay, R 2 (hSMN-FL) = 0.815, R 2 (hSMN S290D) = 0.854, R 2 (hSMN S290A) = 0.846). ( F ) Representative fluorescence images display NSC34 cells expressing GFP-tagged hSMN-FL, hSMN S290D or S290A. Scale bar represents 20 um. ( G ) Nuclear bodies (NBs) were quantified in NSC34 cells expressing hSMN-FL, hSMN S290D or hSMN S290A (mean +- SEM, n = 3, one-way ANOVA with Sidak post-test, ** p < 0.01). ( H , I ) NSC34 cells and ( J , K ) HEK 293T cells expressing GFP, GFP-tagged hSMN-FL, hSMN S290D and hSMN S290A ( H , I ) 48 h or ( J , K ) 24 h post-transfection. Co-immunoprecipitation of either ( H , I ) endogenous SMN and hSMN constructs or ( J , K ) ZPR1 and hSMN constructs were performed and determined by Western blot analysis. #, unspecific band. ( I ) Ratios of endogenous SMN to hSMN construct protein